Cardiologists Want Concrete Guidance From FDA Panel On Stent Thrombosis
This article was originally published in The Gray Sheet
Executive Summary
Cardiologists are looking to an FDA expert panel meeting this Thursday and Friday for tangible advice about drug-eluting stent use in the face of newly discovered safety risks
You may also be interested in...
Drug-Eluting Stent Panelists Could Not Agree On Definition Of Thrombosis
FDA advisory panel members examining the risks of thrombosis in on- and off-label use of drug-eluting stents earlier this month could not reach a consensus on which definition of thrombosis to use
Drug-Eluting Stent Panelists Could Not Agree On Definition Of Thrombosis
FDA advisory panel members examining the risks of thrombosis in on- and off-label use of drug-eluting stents earlier this month could not reach a consensus on which definition of thrombosis to use
Companies Response To Thrombosis Data Differs; New Definition Unveiled
Boston Scientific and Johnson & Johnson/Cordis had markedly different responses to analyses reported last week at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C. showing an increased risk of thrombosis from use of their drug-eluting stents (DES)